The investigators used a June 2026 electronic health record release encompassing 4.95 million patients as the primary data source. From that reservoir, 156,051 patients had breast cancer diagnostic codes and formed the starting sampling frame. The authors reported that cohort construction and downstream processing were executed within Muse Spark and coordinated through a Symbiotic Agent Teaming (SAT) architecture under investigator direction. The source did not report additional demographic breakdowns, dosing details, or confirmatory manual chart reviews for identified orders. The dataset used in the study consisted of licensed third-party patient-level records and is not publicly redistributed; accompanying materials provide aggregate outputs, operational definitions, and limited code for auditing reported counts and figure generation but do not reproduce patient-level cohort selection.
The clinical use case focused on sequential orders of two antibody–drug conjugates: sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd). The main clinical measure was the second-drug record span, defined in the manuscript as the interval from the first order (of the first ADC) to the last order (of the second ADC). This is a record-based interval; the authors explicitly stated that orders did not confirm actual administration or document progression events. The workflow identified 106 patients meeting the sequential-order criteria: 73 had T-DXd ordered first and 33 had SG ordered first. Median second-drug spans were reported as 63 days (interquartile range [IQR], 29–116) for SG following T-DXd, and 49 days (IQR, 21–126) for T-DXd following SG. The median difference between these spans was −14 days with a 95% bootstrap confidence interval of −41 to 21; the distributional P value reported was 0.42. The analysis was descriptive and unadjusted; the manuscript did not include covariate adjustment, survival endpoints, or time-to-event modeling beyond these interval summaries.
The technical workflow combined multi-agent artificial intelligence tools with human oversight, a paradigm the authors termed Human-Guided Orchestration (HGO). Muse Spark handled cohort construction, executable statistical analyses, data-quality checks, literature retrieval, and reporting tasks. These steps were executed through Symbiotic Agent Teaming (SAT) under investigator direction, with Expert-in-the-Loop (EITL) adjudication used to refine outputs. The study team observed that computational execution produced interpretable outputs which were then reviewed and refined by human investigators. The source described these process elements but did not provide algorithmic parameters, agent decision rules, or detailed validation metrics for the automated components in the main text.
Beyond interval summaries, the reported outputs included cohort definitions, aggregate analyses, figures, an evidence context, and a preliminary draft manuscript. The authors shared accompanying files that contain operational definitions and code sufficient for a limited audit of publicly reported counts and figure generation; that code does not reproduce cohort selection, patient-level statistics, or clinical validation. Patient-level records remain licensed third-party data and are not redistributed, and no public repository DOI or claim of independent reproduction was provided. The study therefore enables inspection of aggregated results and workflow artifacts but does not permit external parties to fully reproduce the patient-level selection or confirm individual records from the release.
The authors noted several constraints embedded in the dataset and methods. Orders were used as the proxy measure; the presence of an order in the record did not confirm medication administration or clinical progression. Analyses were descriptive and unadjusted; the manuscript did not attempt causal inference or adjusted effect estimation. Patient-level data were subject to licensing restrictions and were not shared, limiting independent reproduction. Ethical oversight was addressed: the study used retrospective, deidentified clinical data and was determined IRB exempt with waivers of patient informed consent by Bluebonnet IRB under 45 CFR 46.104(d)(4). The manuscript is a preprint and has not undergone peer review. Remaining unanswered questions documented in the source include whether order-based intervals correspond to clinical treatment durations or outcomes, how automated cohort definitions perform against manual chart adjudication, and how the HGO/SAT approach scales and validates across additional clinical questions. The study ends on these practical limitations and open validation steps rather than on broad generalizations.